Kelly A. Demerino
Corporate Officer/Principal at NUVO PHARMACEUTICALS INC.
Kelly A. Demerino active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 2020-12-31 | - |
| Comptroller/Controller/Auditor | 2018-12-31 | 2019-12-31 | |
| Director of Finance/CFO | 2019-12-31 | 2020-12-31 |
Career history of Kelly A. Demerino
Training of Kelly A. Demerino
| Mount Allison University | Undergraduate Degree |
Statistics
International
| Canada | 3 |
Operational
| Comptroller/Controller/Auditor | 1 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Kelly A. Demerino
- Experience
